UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ARGENTUM PHARMACEUTICALS LLC,

Petitioner

V.

NOVARTIS A.G.,

Patent Owner.

Case IPR2017-01550

Patent 9,187,405

DECLARATION OF ROBERT W. TRENCHARD IN SUPPORT OF MOTION FOR ADMISSION PRO HAC VICE

Mail Stop Patent Board Patent Trial and Appeal Board Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

DOCKET

Argentum v. Novartis

A L A R M Find authenticated court documents without watermarks at <u>docketalarm.com</u>.

I, Robert W. Trenchard, declare as follows:

1. I am a litigation partner at Gibson, Dunn & Crutcher LLP.

2. I am a member in good standing of the Bar of the States of New York and New Jersey. I am also admitted to practice before the United States Courts of Appeals for the Third, Seventh, and D.C. Circuits, and the United States District Court for the Southern District of New York.

3. My New York Bar membership No. is 2679488. My New Jersey Bar membership No. is 053551994.

4. I have been practicing law for 22 years, including litigating patent cases for the last 7 years before the Board and in district court. Before the Board, I have been involved in four patent interference proceedings and two *inter partes* review proceedings:

- Sugano v. Goeddel, Patent Interference No. 105,334
- Sugano v. Goeddel, Patent Interference No. 105,337
- Protiva Biotherapeutics, Inc. v, Alnylam Pharmaceuticals Inc., Patent Interference No. 105,792
- Schwindt v. Miller, Patent Interference No. 105,805
- Merck Sharp & Dohme Corp. v. Mayne Pharma International PTY Ltd.,
 IPR2016-01186

• Torrent Pharmaceuticals Limited v. Novartis AG and Mitsubishi Pharma Corp., IPR2014-00784

5. More generally, I represent Novartis in litigating pharmaceutical patent cases, including the following infringement cases in the District of New Jersey:

- Novartis Pharmaceuticals Corp., et al. v. Wockhardt USA, LLC, et al., Civil Action No. 12-cv-3967
- Novartis Pharmaceuticals Corp., et al. v. Wockhardt USA, LLC, et al., Civil Action No. 13-cv-1028
- Novartis Pharmaceuticals Corp., et al. v. Accord Healthcare Inc., et al., Civil Action No. 13-cv-2379
- Novartis Pharmaceuticals Corp., et al. v. Wockhardt USA, LLC, et al., Civil Action No. 13-cv-4669
- Novartis Pharmaceuticals Corp., et al. v. Akorn, Inc., et al., Civil Action No. 13-cv-5125
- Novartis Pharmaceuticals Corp., et al. v. Wockhardt USA, LLC, et al., Civil Action No. 1 3-cv-6835
- Novartis Pharmaceuticals Corp. v. Accord Healthcare Inc., Civil Action No. 13-cv-7178
- Novartis Pharmaceuticals Corp. v. Fresenius Kabi USA, LLC, Civil Action No. 13-cv-7914

- Novartis Pharmaceuticals Corp. v. Pharmaceutics International, Inc., Civil Action No. 14-cv-1347
- Novartis Pharmaceuticals Corp. v. Gland Pharma Ltd, Civil Action No. 14-cv-1841

6. Further, I have represented Novartis in litigating pharmaceutical patent cases involving GILENYA®, including the following infringement cases in the District of Delaware:

- Novartis AG et al v. Actavis Elizabeth LLC, Civil Action No. 14-cv-01487
- Novartis AG et al v. Ezra Ventures LLC, Civil Action No. 15-cv-00150
- Novartis AG et al v. Apotex Inc. et al, Civil Action No. 15-cv-00975
- Novartis AG et al v. HEC Pharm Co. Ltd. et al, Civil Action No. 15-cv-00151

7. I have never been suspended, disbarred, sanctioned or cited for contempt by any court or administrative body.

8. I have never had a court deny my application for admission to practice.

9. In the past three years, I have applied for *pro hac vice* admission before the United States Patent and Trademark Office in the following *inter partes* review proceedings:

Find authenticated court documents without watermarks at docketalarm.com.

M

- Torrent Pharmaceuticals Ltd. v. Novartis AG and Mitsubishi Pharma Corp., IPR2014-00784; and
- Merck Sharp & Dohme Corp. v. Mayne Pharma International Pty Ltd., IPR2016-01186.

The Board granted the motion for my admission *pro hac vice* in the *Torrent Pharmaceuticals* proceeding and has not yet ruled on my application in the *Merck Sharp & Dohme Corp.* proceeding. *Torrent Pharmaceuticals Ltd. v. Novartis AG and Mitsubishi Pharma Corp.*, IPR2014-00784, Paper 8 at 2. (Ex. 2002); Merck *Sharp & Dohme Corp. v. Mayne Pharma Int'l PTY Ltd.*, IPR2016-01186.

10. I am familiar with the subject matter of this proceeding. In addition to U.S. Pat. No. 9,187,405 ("the '405 patent") and its prosecution history, I am familiar with the technology at issue and with GILENYA®, the pharmaceutical product for which the '405 patent is listed in the Orange Book.

11. In connection with my work on GILENYA®, I have become familiar with the prior art references that are the subject of this proceeding.

12. Given my familiarity with the underlying facts and my litigation experience with the Federal Rules of Evidence, I have experience and expertise important to representing Novartis's interests in this matter.

13. I have read and will comply with the Office Patent Trial Practice Guide and the Board's Rules of Practice for Trials, as set forth in Part 42 of 37 C.F.R.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.